+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sensorineural Hearing Loss Drug"

From
Sensorineural Hearing Loss - Pipeline Insight, 2024 - Product Thumbnail Image

Sensorineural Hearing Loss - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 50 Pages
  • Global
From
Sudden Sensorineural hearing loss (SSNHL) - Pipeline Insight, 2024 - Product Thumbnail Image

Sudden Sensorineural hearing loss (SSNHL) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Neuroprotection - Methods, Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Methods, Drugs, Markets and Companies

  • Report
  • November 2021
  • 844 Pages
  • Global
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Sensorineural Hearing Loss (SNHL) is a type of hearing loss caused by damage to the inner ear or auditory nerve. It is the most common type of hearing loss and is usually permanent. SNHL is typically treated with hearing aids, cochlear implants, and other assistive devices. In some cases, drugs may be used to treat SNHL. Central Nervous System (CNS) drugs are used to treat a variety of conditions, including SNHL. These drugs are designed to target the auditory nerve and inner ear, and can help improve hearing in some cases. Common CNS drugs used to treat SNHL include corticosteroids, anticonvulsants, and anti-inflammatory drugs. These drugs can help reduce inflammation and improve nerve function, which can help improve hearing. The Sensorineural Hearing Loss Drug market is a rapidly growing sector of the CNS drug market. Companies in this market are focused on developing drugs to treat SNHL, as well as other hearing-related conditions. Some of the major companies in this market include GlaxoSmithKline, Novartis, Pfizer, Merck, and Sanofi. Show Less Read more